Big Law
Merck Acquires Acceleron Pharma in a $11.5 Billion Deal
Merck will spend about $11.5 billion to buy Acceleron Pharma and its potential treatment for high blood pressure in vessels that connect the lungs heart.
Merck will pay $180 per share in cash for Acceleron, the Kenilworth, New Jersey, company said Thursday.
Acceleron is running late-stage studies of a potential treatment for patients with pulmonary arterial hypertension, a potentially life-threatening blood vessel disorder.